within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX18_Reboxetine;

model Reboxetine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.94,
    Cl = 9.444444444444444e-07,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.026,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Reboxetine</td></tr><tr><td>ATC code:</td><td>N06AX18</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>26</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) used for the treatment of major depressive disorder. It is approved in several countries (e.g., some countries in Europe, but not the United States) for adult patients with depression.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Fleishaker, JC (2000). Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. <i>Clinical pharmacokinetics</i> 39(6) 413–427. DOI:<a href=\"https://doi.org/10.2165/00003088-200039060-00003\">10.2165/00003088-200039060-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11192474/\">https://pubmed.ncbi.nlm.nih.gov/11192474</a></p></li><li><p>Hendershot, PE, et al., &amp; Poland, RE (2001). Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. <i>Psychopharmacology</i> 155(2) 148–153. DOI:<a href=\"https://doi.org/10.1007/s002130100696\">10.1007/s002130100696</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11401003/\">https://pubmed.ncbi.nlm.nih.gov/11401003</a></p></li><li><p>Kasper, S, et al., &amp; Hilger, E (2000). Reboxetine: the first selective noradrenaline re-uptake inhibitor. <i>Expert opinion on pharmacotherapy</i> 1(4) 771–782. DOI:<a href=\"https://doi.org/10.1517/14656566.1.4.771\">10.1517/14656566.1.4.771</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11249515/\">https://pubmed.ncbi.nlm.nih.gov/11249515</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX18 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Reboxetine;
